Paul Giles, MD
Interventional Cardiology · Vidalia, GANPI 1104827369
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,062 of the $3,313 with a category attached, or 62.2%. Boston Scientific accounts for 80.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,846 and has fallen 95.4% since, to $131 in 2025. That places this record below the midpoint for interventional cardiology clinicians in GA, where the typical reported total is $7,640.
Across 32 payments — averaging $103.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Inari Medical, Inc.$249
- Medtronic$185
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
- Abbott$52
- Abiomed$46
- plus $40 from 1 others
What the payments were for
- Travel & lodging$2,06262%
- Food & beverage$1,25138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $2,677 |
| Inari Medical, Inc. | 12 | $249 |
| Medtronic(2 entities) | 5 | $185 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $64 |
| Abbott | 3 | $52 |
| Abiomed | 1 | $46 |
| Stryker | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EKOSONIC$2,677
How this compares
$3,313 in reported general payments places this provider in the 25th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 91 | $81,615 |
| EliquisApixaban | 59 | $54,952 |
| JardianceEmpagliflozin | 34 | $28,789 |
| EntrestoSacubitril/Valsartan | 21 | $16,962 |
| Labetalol Hcl | 76 | $1,431 |
| Metoprolol Succinate | 112 | $1,087 |
| ClopidogrelClopidogrel Bisulfate | 225 | $949 |
| Lisinopril | 178 | $811 |
| Acebutolol Hcl | 14 | $663 |
| Ranolazine ErRanolazine | 14 | $587 |
| Valsartan | 24 | $561 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $554 |
| Potassium Chloride | 52 | $483 |
| Carvedilol | 87 | $471 |
| Prasugrel Hcl | 11 | $460 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Vidalia
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
- Katherine KunkelAtlanta$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.